Previous close | 12,156.00 |
Open | 12,092.00 |
Bid | 11,500.00 x 0 |
Ask | 12,200.00 x 0 |
Day's range | 12,010.00 - 12,178.00 |
52-week range | 9,461.00 - 12,488.00 |
Volume | |
Avg. volume | 2,939,169 |
Market cap | 188.446B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 37.31 |
EPS (TTM) | 3.23 |
Earnings date | 25 Jul 2024 |
Forward dividend & yield | 2.28 (1.89%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | 126.95 |
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).